Promising phase IIb data on Clazakizumab in patients with moderate-to-severe rheumatoid arthritis to be presented
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the…
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...